Navigation Links
Quest Diagnostics Announces Final Tender Offer Results
Date:11/20/2009

MADISON, N.J., Nov. 20 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (the "Company") (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today the final results for its previously announced cash tender offer (the "Tender Offer") to purchase any and all of its 5.125% Senior Notes due 2010 and any and all of its 7.50% Senior Notes due 2011 (collectively, the "Notes"). Additional terms and conditions of the Tender Offer are set forth in the offer to purchase dated November 12, 2009 and the related letter of transmittal. The settlement date for the Tender Offer will be today, November 20, 2009.

The table below identifies the principal amount of each series of Notes validly tendered and accepted for purchase by the Company.


                                                           Percentage of
                                                          Principal Amount
            Title of     Aggregate      Principal Amount     Outstanding
            Series of  Principal Amount  Tendered and         Tendered
CUSIP No.  Securities   Outstanding       Accepted          and Accepted
---------  ----------  ---------------- ----------------  ----------------

74834LAK6    5.125%     $226,363,000      $60,829,000           26.87%
          Senior Notes
           due 2010

74834LAE0    7.50%      $248,637,000      $89,369,000           35.94%
          Senior Notes
           due 2011

The Company retained BofA Merrill Lynch as Global Coordinator & Joint Lead Dealer Manager and Morgan Stanley, RBS and Wells Fargo Securities as Joint Lead Dealer Managers. Global Bondholder Services Corporation was retained to serve as the Depositary and to serve as the Information Agent for the Tender Offer.

For additional information regarding the terms of the Tender Offer, please contact: BofA Merrill Lynch at (888) 292-0070 (toll free) or (980) 388-4603 (collect).

About Quest Diagnostics

Quest Diagnostics is the world's leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at www.QuestDiagnostics.com.

The statements in this press release which are not historical facts may be forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management's current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, changes in government regulations, changing relationships with customers, payers, suppliers and strategic partners and other factors discussed in "Business," "Risk Factors," "Cautionary Factors that May Affect Future Results," "Legal Proceedings," "Management's Discussion and Analysis of Financial Condition and Results of Operations," and "Quantitative and Qualitative Disclosures About Market Risk" in the Company's 2008 Annual Report on Form 10-K and "Management's Discussion and Analysis of Financial Condition and Results of Operations," "Quantitative and Qualitative Disclosures About Market Risk" and "Risk Factors" in the Company's 2009 Quarterly Reports on Form 10-Q and other items throughout the Form 10-K and the Company's 2009 Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.

Media Contact: Kathleen Valentine, Investors, +1-973-520-2900, or Wendy Bost, Media, +1-973-520-2800, both for Quest Diagnostics Incorporated

SOURCE Quest Diagnostics Incorporated


'/>"/>
SOURCE Quest Diagnostics Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U.S. Workforce, According to Quest Diagnostics Drug Testing Index(TM)
2. Study Raises New Questions About Cholesterol Drug Zetia
3. New Study Raises New Questions About Cholesterol Drug Zetia
4. Quest Diagnostics to Speak at the Lazard Capital Markets 6th Annual Healthcare Conference
5. FDA Questions Safety of Caffeinated Alcoholic Drinks
6. Cholesterol and Cancer: Answers and Some New Questions
7. MDS Inc. and Danaher Corporation Receive Second Request for Information from U.S. Federal Trade Commission for MDS Analytical Technologies Sale
8. Study spotlights efficacy of questionnaire to identify patients at high risk for lung cancer
9. Halloween sex offender policies questioned
10. Your Questions Answered Online About Plastic and Cosmetic Surgery
11. Study questions need for routine intervention in patients with renovascular disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Texas (PRWEB) , ... March 23, 2017 , ... ... Command (USSOCOM) awarded Task Force Dagger Foundation the US Special Operations Command’s Patriot ... During the presentation, General Thomas thanked Task Force Dagger Foundation for its significant ...
(Date:3/23/2017)... ... March 23, 2017 , ... The Boulevard is honored to host Shriners ... events will be located in the Main West Entrance of The Boulevard (in front ... No appointment is necessary and each child with a parent or guardian will be ...
(Date:3/23/2017)... ... March 23, 2017 , ... News Advisory/Interview Opportunity , After six years of ... victory in Europe for public health and the environment and is calling on the ... research and the overwhelming support of European citizens, the European Union (EU) will, beginning ...
(Date:3/23/2017)... ... March 23, 2017 , ... “Wounded Woman Be Ye Healed-Passing ... Ye Healed-Passing On A Legacy” is the creation of published author, Desiree M Webb, ... grief ministry. She has been happily married to her husband, Paul, for over ...
(Date:3/23/2017)... ... March 23, 2017 , ... Ogden Clinic, the largest ... centric payment system, to expand its focus on patient care by providing an ... , “At Ogden Clinic, we are working to become a different type ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... , Mar 23, 2017 Research and Markets ... 2017-2021" report to their offering. ... The global capillary electrophoresis market to grow ... The report, Global Capillary Electrophoresis Market 2017-2021, has been prepared ... The report covers the market landscape and its growth prospects over ...
(Date:3/23/2017)... -- Drug diversion is a significant contributing factor in ... new oral fluid monitoring test, announced today by ... detailed and actionable information to clinicians than urine ... patient safety, and help to identify drug diversion. ... Evaluation (CORE) system is the first patient-monitoring screening ...
(Date:3/23/2017)... 2017  A new genetic test has been ... individuals who carry HLA-B*15:02 and who ... potentially deadly side effect of certain medications used ... HLA-B*15:02 is strongly associated with life-threatening ... and toxic epidermal necrolysis in patients treated with ...
Breaking Medicine Technology: